• Kayentis

  Led · Equity · Mar 2023

  Kayentis provides electronic Clinical Outcome Assessment (eCOA) and decentralized/hybrid clinical trial (DCT) solutions to pharma, biotech and CROs. Led by CEO Guillaume Juge and active since 2003, the company supports phases II/III across a broad range of therapeutic areas and has expanded its services beyond eCOA to meet decentralized trial needs. Kayentis has conducted digital data collection for over 280 clinical trials in 85 countries, covering 18,000 sites and 98,000 patients in 120 languages, and employs 185 staff. It maintains offices in Boston, Grenoble and Tokyo and reports that U.S.-based sponsor teams lead about one-third of its projects. The company raised an additional €5M—€2.2M as increased capital from LBO France, Extens and Bpifrance and €2.8M in bank loans—to support growth. Kayentis intends to use the funds to scale up its North American operations to support clinical trials. Kayentis provides digital data capture technologies and eCOA solutions for sponsors, sites and patients in clinical trials, with a focus on phase II/III research. The company has been active in clinical development since 2003 and has specialized in eCOA over the past ten years while expanding into hybrid and decentralized trials. Its core product is the Clin’form3 eCOA platform, which Kayentis is enriching with new functions and apps to integrate with other clinical databases and adapt to clinical workflows. Kayentis has conducted digital data collection for over 220 clinical trials in 79 countries, covering 13,000 sites, 80,000 patients and 120 languages. Headquartered in Grenoble, France, the company also has operations in Boston and Tokyo and is led by CEO Guillaume Juge. The company plans to improve patient and site experience through televisits, eConsent and wearable integrations and to intensify US development. Kayentis develops electronic clinical outcome assessment (eCOA) solutions delivered via web portals and mobile tools, including patient-reported, clinician-reported, and observer-reported outcomes, automatic remote testing, and patient diaries. The company emphasizes patient engagement to improve data quality, compliance, and trial efficiency. It is a seven-year-old French firm whose platform has been used in more than 120 trials across 75 countries, impacting roughly 50,000 patients. Kayentis raised $3.9 million (3.6 million euros) in the reported funding round to support its growth. Management says the financing validates its development model and growth prospects and will fund continued platform improvements and value-added services. The company plans to use the funds to accelerate international expansion and to grow its sales, marketing, and R&D teams.

• Discngine

  Led · Series A · Dec 2017

  Discngine develops software applications for the research departments of life sciences companies, specializing in work related to active molecule discovery. Established in 2004 by two of Pfizer’s research alumni and led by founder and CEO Eric Le Roux, the company is based in Paris. Its offering evolved from custom software to licenses for software components and business solutions. Discngine is running a two-year R&D program, 3decision®, to build a collaborative large-scale three-dimensional data management application for biomolecules; the program began in March 2018. The R&D aims to enable users to consult, manage, and communicate around structural data for a wide range of biomolecules and to support a commercial launch. Clients include world leaders in the pharmaceutical, cosmetics, and agrochemical industries. The company plans to focus on offering catalog products through SaaS and cloud-based subscription models and has secured external funding to support the program. Discngine develops software applications for research departments of life sciences companies, specializing in workflows related to active molecule discovery. The company has historically offered custom software and licensed components and business solutions, and is now shifting to catalog products via SaaS and cloud subscriptions. It is collaborating with Dassault Systèmes BIOVIA to distribute its first two SaaS solutions and plans to launch additional life-sciences research solutions in 2018. Discngine was founded in 2004 by two former Pfizer researchers and is led by CEO Eric Le Roux. The company currently employs 38 people and counts world leaders in the pharmaceutical, cosmetics and agrochemical industries among its clients. The recent financing is intended to accelerate product development and commercialization and to support international expansion.

No current team members are available.